The value of healthcare M&A in H1 surpassed pre-pandemic levels -
Healthcare M&A (including pharma, biotech and medical) saw strong growth over the first half of 2021 as investors continued to pursue deal opportunities in...more
7/30/2021
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Domestic Dealmaking ,
Global Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)